Compare IDEXX Laboratories, Inc. (IDXX) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs 22nd Century Group Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: IDEXX Laboratories, Inc. is far larger — about 65034.5× 22nd Century Group Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 45,625). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and 22nd Century Group Inc for 32 Days on average.
| IDXX | XXII | |
|---|---|---|
Market Cap | $40.43B | $621.67K |
Volume | 692,164 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $483.00 |
52-Week Low | $504.70 | $0.80 |
Typical Hold Time | 46 Days | 32 Days |
Enterprise Value | $41.32B | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
